Primary resistance to afatinib in a patient with NSCLC harboring EGFR p.E709_T710delinsD and brain metastases: a case report and literature review
- 1Department of Respiratory Medicine, Changde Hospital, Xiangya School of Medicine, Central South University (The First People’s Hospital of Changde City)
- 2Department of Oncology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People’s Hospital of Changde City)
Abstract
EGFR p.E709_T710delinsD is a rare in-frame deletion-insertion P-loop and alpha-C-helix compressing (PACC) mutation of EGFR exon 18. Current evidence suggests that patients with non-small cell lung cancer (NSCLC) harboring this variant generally respond to afatinib. However, primary resistance to afatinib in this molecular subset is rarely reported. We report a 68-year-old man diagnosed with stage IV lung adenocarcinoma harboring an EGFR p.E709_T710delinsD mutation (variant allele frequency, 45.9%) with co-occurring EGFR amplification (fold change 1.5). Brain metastases were present at baseline. The patient was treated with oral afatinib at an initial dose of 30 mg once daily but the disease progressed rapidly, suggesting possible primary targeted resistance. The patient died 5 weeks later. This case represents a rare example of primary resistance to afatinib in non-small cell lung cancer (NSCLC) harboring the EGFR p.E709_T710delinsD mutation. Given the lack of tissue and molecular evidence to confirm the resistance mechanism in this case, this report combines previous literature to explore the potential factors associated with treatment failure and their clinical implications. This case does not refute the overall sensitivity of this variant to afatinib, but suggests that in patients with high baseline disease burden and aggressive tumor biology, this variant may present as a phenotype with no initial benefit and rapid progression. For such rapidly progressive cases, early radiographic reassessment should be performed, and repeat biopsy or circulating tumor DNA (ctDNA) testing should be pursued as soon as safely feasible to clarify the resistance mechanism and guide subsequent treatment.
Related
- Successful salvage therapy with glofitamab followed by selinexor maintenance in an elderly patient with primary refractory diffuse large b-cell lymphoma harboring TP53 and CD58 mutations: a case report and literature review
- Metachronous multiple insulinomas in oculo-facio-cardio-dental syndrome harboring a novel BCOR deletion: a case report with review of literature
- Compressive Goiter Hiding Clear Cell Renal Cell Carcinoma Metastases to the Thyroid Gland—Report of a Rare Case and Literature Review
- First-Line Lorlatinib for ALK-Rearranged Pulmonary Large-Cell Neuroendocrine Carcinoma with Brain Metastases and Suspected Leptomeningeal Involvement: A Case Report and Literature Review
- Primary pulmonary choriocarcinoma with brain metastases in a male: a case report and literature review
BibTeX
@article{dong2026primary,
title = {{Primary resistance to afatinib in a patient with NSCLC harboring EGFR p.E709_T710delinsD and brain metastases: a case report and literature review}},
author = {Su-Su Dong and Xuan Zhang and Wen Dong},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1981577},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1981577/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Primary resistance to afatinib in a patient with NSCLC harboring EGFR p.E709_T710delinsD and brain metastases: a case report and literature review
AU - Su-Su Dong
AU - Xuan Zhang
AU - Wen Dong
PY - 2026
DA - 2026/10/26
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1981577
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1981577/full
AB - EGFR p.E709_T710delinsD is a rare in-frame deletion-insertion P-loop and alpha-C-helix compressing (PACC) mutation of EGFR exon 18. Current evidence suggests that patients with non-small cell lung cancer (NSCLC) harboring this variant generally respond to afatinib. However, primary resistance to afatinib in this molecular subset is rarely reported. We report a 68-year-old man diagnosed with stage IV lung adenocarcinoma harboring an EGFR p.E709_T710delinsD mutation (variant allele frequency, 45.9%) with co-occurring EGFR amplification (fold change 1.5). Brain metastases were present at baseline. The patient was treated with oral afatinib at an initial dose of 30 mg once daily but the disease progressed rapidly, suggesting possible primary targeted resistance. The patient died 5 weeks later. This case represents a rare example of primary resistance to afatinib in non-small cell lung cancer (NSCLC) harboring the EGFR p.E709_T710delinsD mutation. Given the lack of tissue and molecular evidence to confirm the resistance mechanism in this case, this report combines previous literature to explore the potential factors associated with treatment failure and their clinical implications. This case does not refute the overall sensitivity of this variant to afatinib, but suggests that in patients with high baseline disease burden and aggressive tumor biology, this variant may present as a phenotype with no initial benefit and rapid progression. For such rapidly progressive cases, early radiographic reassessment should be performed, and repeat biopsy or circulating tumor DNA (ctDNA) testing should be pursued as soon as safely feasible to clarify the resistance mechanism and guide subsequent treatment.
SN - 2234-943X
ER -